ROCKET PHARMACEUTICALS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

ROCKET PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $77.56 million for the year ending 2025.

  • ROCKET PHARMACEUTICALS, INC. showed a decrease of -52.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2014: $10.94 million | Q2 2014: $8.88 million | Q3 2014: $5.36 million | Q1 2015: $53.14 million | Q2 2015: $49.01 million | Q3 2015: $89.25 million | Q1 2016: $58.71 million | Q2 2016: $38.52 million | Q3 2016: $83.00 million | Q1 2017: $25.27 million | Q2 2017: $27.61 million | Q3 2017: $49.15 million | Q1 2018: $171.14 million | Q2 2018: $52.55 million | Q3 2018: $38.08 million | Q1 2019: $124.46 million | Q2 2019: $64.83 million | Q3 2019: $89.20 million | Q1 2020: $190.52 million | Q2 2020: $163.20 million | Q3 2020: $82.23 million | Q1 2021: $252.54 million | Q2 2021: $264.61 million | Q3 2021: $245.64 million | Q1 2022: $130.55 million | Q2 2022: $187.55 million | Q3 2022: $196.67 million | Q1 2023: $64.58 million | Q2 2023: $45.08 million | Q3 2023: $225.66 million | Q1 2024: $35.28 million | Q2 2024: $38.61 million | Q3 2024: $65.60 million | Q1 2025: $49.81 million | Q2 2025: $32.82 million | Q3 2025: $75.95 million.
  • Over the full 13 years of available data (2013 to 2025), ROCKET PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 506.3%.
  • Historical annual values: Fiscal year 2025: $77.56 million | Fiscal year 2024: $163.64 million | Fiscal year 2023: $55.90 million | Fiscal year 2022: $140.52 million | Fiscal year 2021: $232.69 million | Fiscal year 2020: $297.10 million | Fiscal year 2019: $185.38 million | Fiscal year 2018: $111.36 million | Fiscal year 2017: $18.14 million | Fiscal year 2016: $29.80 million | Fiscal year 2015: $80.04 million | Fiscal year 2014: $3.62 million | Fiscal year 2013: $12.79 million.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: